Minimal Residual Disease Testing Market Propelled by Growing Adoption of Standardized Diagnostic Testing
The Minimal Residual Disease Testing market involves the monitoring of response to anti-cancer therapies by detecting and quantifying residual malignant disease below the threshold of conventional detection methods. It enables assessment of treatment response through detection of cancer cells at frequencies as low as 1 in 104-105 nucleated cells, thereby allowing for treatment strategy modification or selection of consolidation therapy in a timely manner. The ongoing development of sensitive techniques such as next-generation sequencing, multiparameter flow cytometry, and allele-specific polymerase chain reaction (PCR) has made MRD testing commercially feasible.
The Global Minimal Residual Disease Testing Market is estimated to be valued at US$ 2.31 Bn in 2024 and is expected to exhibit a CAGR of 11% over the forecast period 2024 To 2031.
Key Takeaways
Key players operating in the Minimal Residual Disease Testing are Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Adaptive Biotechnologies, Invitae Corporation, ASURAGEN, INC., Invivoscribe, Inc., Laboratory Corporation of America Holdings, Natera, Inc., Sysmex Inostics, Inc., Amgen Inc., FOUNDATION MEDICINE, INC., Sebia, and Myriad Genetics, Inc. Key players are focusing on new product launches, collaborations, and strengthening their distribution networks to gain market share in this emerging field.
The growing demand for Minimal Residual Disease Testing Market Demand can be attributed to increasing cancer prevalence globally as well as a rising focus on standardized cancer care practices. Early detection of treatment response has been shown to reduce unnecessary toxic exposure and enable timely administration of consolidation or salvage therapies to improve patient outcomes.
The adoption of Minimal Residual Disease Testing is also expanding globally with growing awareness regarding its clinical utility. Additionally, pathologists and oncologists across major markets are endorsing its incorporation in treatment guidelines, which is helping establish it as a standard of care for certain cancer types. Ongoing technological advancements are also helping address challenges regarding turnaround time, accessibility and costs.
Get more insights on This Topic- Minimal Residual Disease Testing Market
English
Arabic
Français
Español
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian